



ФЕДЕРАЛЬНАЯ СЛУЖБА ПО НАДЗОРУ В СФЕРЕ ЗДРАВООХРАНЕНИЯ
(РОСЗДРАВНАДЗОР)

РЕГИСТРАЦИОННОЕ УДОСТОВЕРЕНИЕ НА МЕДИЦИНСКОЕ ИЗДЕЛИЕ

от 25 ноября 2011 года № ФСР 2011/12395

На медицинское изделие

Набор реагентов для определения гемоглобина в крови гемиглобинцианидным методом «Гемоглобин-Агат» по ТУ 9398-280-11498242-00

Настоящее регистрационное удостоверение выдано

Общество с ограниченной ответственностью "Агат-Мед" (ООО "Агат-Мед"),
Россия, 105173, Москва, поселок Восточный, ул. Главная, д. 6, кв. 12

Производитель

Общество с ограниченной ответственностью "Агат-Мед" (ООО "Агат-Мед"),
Россия, 105173, Москва, поселок Восточный, ул. Главная, д. 6, кв. 12

Место производства медицинского изделия

105173, Москва, поселок Восточный, ул. Главная, д. 6, кв. 12

Номер регистрационного досье № 41794 от 19.10.2011

Вид медицинского изделия -

Класс потенциального риска применения медицинского изделия 1


Код Общероссийского классификатора продукции для медицинского изделия 93 9816

Настоящее регистрационное удостоверение имеет приложение на 1 листе

приказом Росздравнадзора от 25 ноября 2011 года № 7750-Пр/11

и приказом от 10 декабря 2013 года № 7123-Пр/13 о замене
допущено к обращению на территории Российской Федерации.

Врио руководителя Федеральной службы
по надзору в сфере здравоохранения


М.А. Мурашко

0005897



Клинически
биохимии

Агат

ООО «Агат-Мед»
105173, г. Москва, ул. Главная, 6-12
тел. (495) 777-41-92
agat@agat.ru www.agat.ru

ПАСПОРТ

Набор контрольных растворов гемоглобина
для биохимических исследований 3 фл. х 5 мл.
«Гемоглобин – Контроль» (Биоконт ГК)
ТУ 9398-275-11498242-00

Серия **57/890322** Дата выпуска **03.2022** Годен до **04.2024**
Количество наборов в серии **1000**

Наименование показателя	Требования ТУ	Результаты анализа
1. Внешний вид		
1.1 Раствор гемоглобина ГК-1 (Кат.№339), ГК-2 (Кат.№340), ГК-3 (Кат.№341)	Жидкость от темно-красного до темно-коричневого цвета	Жидкость темно-красного цвета
2. Технические характеристики		
2.1 Концентрация раствора гемоглобина: ГК-1, г/л, в интервале, ГК-2, г/л, в интервале, ГК-3, г/л, в интервале.	65-75 110-130 145-175	70 121 160
3. Показатели правильности определения		
3.1 Коэффициент вариации результатов определения, %, не более	2,0	соответствует
3.2 Допустимое отклонение от аттестационного значения концентрации гемоглобина, % не более	2,0	соответствует
3.3 Межфлаконная вариация расхождение, %, не более	2,0	соответствует
3.4 Допустимый разброс результатов определения концентрации гемоглобина в разных наборах одной серии, % не более	2,0	соответствует

Заключение ОКК ООО «Агат-Мед»:

Набор серии **57/890322** требованиям ТУ 9398-275-11498242-00 предприятия соответствует.

Начальник ОКК ООО «АГАТ-МЕД» Гладун В.В.

« 03 » марта 2022 г.



М И I



Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: 86-25-68568508 Email: overseas@geteincom.cn Web: www.bio-GP.com.cn

Document No.: GP-GMSQ-2022-110

Letter of Authorization

To whom it may concern,

We, Getein Biotech, Inc. (No.9 BoFu Road, Luhe District, Nanjing, 211505, China), hereby authorize Sanmedico SRL. as our official distributor for registering, promoting, selling, distributing, taking part in tenders, maintaining & after sale technical services of under-mentioned product in the territory of Moldova:

Sanmedico SRL will comply with the laws and regulations of the countries and regions where they are located in and where they are selling mentioned product to, otherwise, the risks and losses arising therefrom shall be undertaken by Sanmedico SRL

This authorization starts from Jan 1, 2022 and will be valid to December 31 2023

Getein Biotech, Inc. has the right to terminate the authorization before validity and will inform Sanmedico SRL with 10 days in advance.

Getein Biotech, Inc.

Name: Steven Zhou

Position: Overseas Sales Director

基蛋生物科技股份有限公司
GETEIN BIOTECH, INC.

A handwritten signature in black ink that reads 'Steven Zhou'.



Declaration of Conformity



according to Directive 98/79/EC, on in vitro diagnostic medical devices

Maker (Name, Address)	Getein Biotech, Inc. No. 9 Bofu Road, Luhe District, Nanjing, 211505, China	
Authorized Representative (Name, Address)	Lotus NL B.V. Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherlands.	
Medical device	Description :	FIA8000 Quantitative Immunoassay Analyzer FIA8600 Quantitative Immunoassay Analyzer Cardiac Troponin I Fast Test Kit One Step Test for cTnI (Colloidal Gold) cTnI Rapid Test (Colloidal Gold Assay) One Step Test for NT-proBNP (Colloidal Gold) One Step Test for NT-proBNP/cTnI (Colloidal Gold) One Step Test for CK-MB/cTnI/Myo (Colloidal Gold) One Step Test for hs-CRP+CRP (Colloidal Gold) One Step Test for D-Dimer (Colloidal Gold) One Step Test for PCT (Colloidal Gold) One Step Test for β 2-MG (Colloidal Gold) One Step Test for mAlb (Colloidal Gold) One Step Test for NGAL (Colloidal Gold) One Step Test for CysC (Colloidal Gold) One Step Test for HCG+ β (Colloidal Gold) One Step Test for HbA1c (Colloidal Gold) One Step Test for PCT/CRP (Colloidal Gold) One Step Test for CK-MB/cTnI/H-FABP (Colloidal Gold) One Step Test for H-FABP (Colloidal Gold) One Step Test for CK-MB/cTnI (Colloidal Gold) One Step Test for CK-MB (Colloidal Gold) One Step Test for TSH (Colloidal Gold) One Step Test for T4/T3 (Colloidal Gold) One Step Test for T3 (Colloidal Gold) One Step Test for T4 (Colloidal Gold) One Step Test for 25-OH-VD (Colloidal Gold) One Step Test for FOB (Colloidal Gold) One Step Test for <i>H. pylori</i> (Colloidal Gold) One Step Test for SAA (Colloidal Gold) Getein1100 Immunofluorescence Quantitative Analyzer Getein1600 Immunofluorescence Quantitative Analyzer Getein1180 Immunofluorescence Quantitative Analyzer Getein1200 Immunofluorescence Quantitative Analyzer Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) NT-proBNP Fast Test Kit (Immunofluorescence Assay) hs-CRP+CRP Fast Test Kit (Immunofluorescence Assay) NT-proBNP/cTnI Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay) D-Dimer Fast Test Kit (Immunofluorescence Assay)



		<p>PCT Fast Test Kit (Immunofluorescence Assay) β2-MG Fast Test Kit (Immunofluorescence Assay) mAlb Fast Test Kit (Immunofluorescence Assay) NGAL Fast Test Kit (Immunofluorescence Assay) CysC Fast Test Kit (Immunofluorescence Assay) CK-MB Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnl Fast Test Kit (Immunofluorescence Assay) HCG+β Fast Test Kit (Immunofluorescence Assay) HbA1c Fast Test Kit (Immunofluorescence Assay) PCT/CRP Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnl/H-FABP Fast Test Kit (Immunofluorescence Assay) H-FABP Fast Test Kit (Immunofluorescence Assay) 25-OH-VD Fast Test Kit (Immunofluorescence Assay) TSH Fast Test Kit (Immunofluorescence Assay) T3 Fast Test Kit (Immunofluorescence Assay) T4 Fast Test Kit (Immunofluorescence Assay) 25-OH-VD Fast Test Kit (Immunofluorescence Assay) FOB Fast Test Kit (Immunofluorescence Assay) <i>H. pylori</i> Fast Test Kit (Immunofluorescence Assay) SAA Fast Test Kit (Immunofluorescence Assay) LH Fast Test Kit (Immunofluorescence Assay) FSH Fast Test Kit (Immunofluorescence Assay) AMH Fast Test Kit (Immunofluorescence Assay) PRL Fast Test Kit (Immunofluorescence Assay) CK-MB Control cTnl Control Myo Control NT-proBNP Control D-Dimer Control CRP Control PCT Control β2-MG Control mAlb Control NGAL Control CysC Control H-FABP Control HbA1c Control HCG+β Control CK-MB/cTnl/Myo Control CK-MB/cTnl Control NT-proBNP/cTnl Control TSH Control T4/T3 Control T3 Control T4 Control</p>	
	Classification of products according to directive	:	Others
	Batch/serial No. Type, production term (if applicable)	:	



Applicable coordination standards:	EN ISO 14971:2012	EN ISO 23640:2015	EN ISO 13485:2016
	EN 13612:2002	EN ISO15223-1:2012	EN ISO 18113-2:2011
	EN 1041:2008	EN ISO 18113-1:2011	EN ISO 18113-3:2011
	IEC 61010-1:2010	IEC 61010-2-081:2015	IEC 61010-2-101:2015
	IEC 61326-1:2013	IEC 61326-2-2:2013	

Signatory representative declares herein the above mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex III. This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by TÜV Rheinland (Shanghai) Co., Ltd.

General Manager: Enben Su

Nha Trang, 20th, Jul, 2019
 (place and date of issue)

_____ 
 (name and signature or equivalent marking of authorized person)




Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that: **Getein Biotech, Inc.**
No.9 Bofu Road
Luhe District
Nanjing
Jiangsu
211505
China

基蛋生物科技股份有限公司
中国
江苏省
南京市
六合区
沿江工业开发区
博富路9号
邮编: 211505

Holds Certificate No: **MD 728432**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay). Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay).

研发, 生产和销售化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂。

研发, 生产和销售用于化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂配套使用的分析仪。



For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

Original Registration Date: 2020-05-29

Latest Revision Date: 2020-07-22

Effective Date: 2020-07-26

Expiry Date: 2023-07-25

Page: 1 of 1



...making excellence a habit.™



Cardiac Troponin I Fast Test Kit

User Manual

Cat.# CG2001

INTENDED USE

Cardiac Troponin I Fast Test Kit is intended for *in vitro* qualitative and semi-quantitative determination of cardiac Troponin I (cTnI) in serum, plasma or whole blood. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Troponin, a molecular complex that is bound to the thin filament (actin) of striated muscle fibers, acts with intracellular calcium to control the interaction of the thin filament with the thick filament (myosin), thus regulating muscle contraction. Troponin consists of three subunits: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac Troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of Troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardium.

Clinical studies have demonstrated the release of cTnI into the blood stream within hours following acute myocardial infarctions (AMI) or ischemic damage. Elevated levels of cTnI are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnI has become an important marker in the diagnosis and

evaluation of patients suspected of having an AMI.

The current guideline of The Joint European Society of Cardiology/ American College of Cardiology Committee support the use of cTnI as a preferred marker of myocardial injury. Several major studies have shown that cTnI is also a predictor of cardiac risk in patients with unstable angina. The American College of Cardiology and the American Heart Association's current guidelines recommend using troponin results when making treatment decisions regarding unstable angina and non-ST segment elevation MI (NSTEMI).

PRINCIPLE

The test uses an anti-human cTnI monoclonal antibody conjugated with colloidal gold and another anti-human cTnI monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the gold-labelled anti-human cTnI monoclonal antibody binds with the cTnI in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human cTnI monoclonal antibody resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the amount of cTnI in sample.

CONTENTS

A kit contains:

- | | |
|---|----|
| 1. Getein cTnI test card in a sealed pouch with desiccant | 25 |
| 2. Disposable pipet | 25 |
| 3. User manual | 1 |
| 4. Standard colorimetric card | 1 |
| 5. Whole blood buffer | 1 |

A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloid gold pad (coated with gold-labelled anti-human cTnI monoclonal antibody), nitrocellulose membrane (the test line is coated with anti-human cTnI monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Whole blood buffer composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months. Use the test card within 1 hour once the foil pouch is opened. Store the whole blood buffer at 0~30°C with a valid period of 24 months. Store the whole blood buffer at 2~8°C for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for **serum, plasma or whole blood samples. Heparin, EDTA or sodium citrate** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8°C or stored at -20°C for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8°C).

- Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
- Do not use heat-inactivated samples.
- SAMPLE VOLUME:** 80 µl.

TEST PROCEDURE

- Collect specimens according to user manual.
- Test card, sample and reagent should be brought to room temperature before testing.
- Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
- Put the test card on a clean table, horizontally placed.
- Using sample transfer pipette, deliver 80 µl of sample (or 3 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 80 µl sample on the test card).
- Read the results visually in 15 minutes.** For semi-quantitative interpretation of results, please refer to the standard colorimetric card.

TEST RESULTS

Negative: A single purplish red band appears at the control area (C) without any other band at test line is a valid negative result, indicating the concentration of cTnI in the sample is below the cut-off value.

Positive: A single purplish red band appears at the control area (C) and a purplish red colored band appears in test line is a valid positive result. The intensity of the purplish red color in the test line helps to read the semi-quantitative result visually according to the standard colorimetric card:

Color intensity	Reference Concentration (ng/ml)
—	<0.3
+ —	0.3~1
+	1~5
++	5~15
+++	15~30
++++	30~50
++++	>50

Invalid: If no colored band appears in the control area (C) in 15 minutes, the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

The expected normal value for Troponin I was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.3 ng/ml, (The probability that value of a normal person below 0.3 ng/ml is 99%). cTnI concentration less than 0.3 ng/ml can be estimated as normal.

It is recommended that each laboratory establish its own expected values for the population it serves.

LIMITATIONS

As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.

REFERENCES

- Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
- EN ISO 18113-1:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
- EN ISO 18113-2:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use (ISO18113-2:2011).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on Cardiac Troponin I Fast Test Kit are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223 – 1 : 2012.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	In vitro diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing Cardiac Troponin I Fast Test Kit. Please read this user manual carefully before operating to ensure proper use.

Version: WCG01A-DX-S-02



Getein Biotech, Inc.

Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China

Tel: +86-25-68568508

Fax: +86-25-68568500

E-mail: tech@getein.com.cn

overseas@getein.com.cn

Website: www.bio-gp.com.cn



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co.,LTD

STATEMENT

We, Zhejiang Orient Gene Biotech Co., Ltd , having a registered office at 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as non-exclusive authorized representative for Orient Gene Brand product in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement letter will be valid from Feb.21th,2023 to Feb.20th, 2024.

Zhejiang Orient Gene Biotech Co., Ltd

General Manager:

Date:2023/2/21



地址：浙江省湖州市安吉县递铺镇阳光大道东段 3787 号
Add: 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China
电话 Tel:+86-572-5226111 传真 Fax: +86-572-5226222 邮编 P.C.:313300



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG060
Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Fecal Occult Blood Rapid Test Strip (Feces)	GEFOB-601b
Fecal Occult Blood Rapid Test Cassette (Feces)	GEFOB-602b

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: Shanghai International Holding Corp. GmbH (Europe)

EC Representative's Address: Eiffestrasse 80, 20537 Hamburg, Germany

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 28, 2017

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President



Benannt durch/Designated by
Zentralstelle der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
www.zlg.de
ZLG-BS-245.10.07



Product Service

EC Certificate

EC Design-Examination Certificate

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV (4) (List A)

No. V7 092378 0009 Rev. 00

Manufacturer:

**Healgen Scientific Limited
Liability Company**

3818 Fuqua Street
Houston TX 77047
USA

Product:

Screening test for Hepatitis C marker

The Certification Body of TÜV SÜD Product Service GmbH declares that a design examination has been carried out on the respective devices in accordance with IVDD Annex IV (4). The design of the devices conforms to the requirements of this Directive. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:V7_092378_0009_Rev.00

Report No.:

713234651

Valid from:

2022-04-22

Valid until:

2025-05-26

Date,

2022-04-22

Christoph Dicks
Head of Certification/Notified Body



Benannt durch/Designated by
 Zentralstelle der Länder
 für Gesundheitsschutz
 bei Arzneimitteln und
 Medizinprodukten
 www.zlg.de
 ZLG-BS-245.10.07



Product Service

EC Certificate

EC Design-Examination Certificate
 Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV (4) (List A)

No. V7 092378 0009 Rev. 00

Model(s):	HCV Hepatitis C Virus Rapid Test	
Facility(ies):	Zhejiang Orient Gene Biotech Co., Ltd. 3787#, East Yangguang Avenue, Dipu Street Anji, 313300 Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA	
Parameters:	Model Name:	Model No.:
	--	
	HCV Hepatitis C Virus Rapid Test (Serum / Plasma) (Cassette)	GCHCV-302a
	HCV Hepatitis C Virus Rapid Test (Whole Blood /Serum / Plasma) (Cassette)	GCHCV-402a



Certificate

No. Q5 092305 0001 Rev. 01

Holder of Certificate: **Zhejiang Orient Gene Biotech Co., Ltd.**
3787#, East Yangguang Avenue, Dipu Street Anji
313300 Huzhou, Zhejiang
PEOPLE'S REPUBLIC OF CHINA

Certification Mark:



Scope of Certificate: **Design and Development, Production and Distribution of In Vitro Diagnostic Reagent and Instrument for the Detection of Drugs of Abuse, Fertility, Infectious Diseases, Oncology, Biochemistry, Cardiac Diseases, Allergic Disease based on Rapid Test, PCR and Liquid Biochip Method.**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 01](http://www.tuvsud.com/ps-cert?q=cert:Q5_092305_0001_Rev.01)

Report No.: SH2198802

Valid from: 2022-04-11

Valid until: 2024-03-16

Date, 2022-04-11



Christoph Dicks

Head of Certification/Notified Body



Product Service

Certificate

No. Q5 092305 0001 Rev. 01

Applied Standard(s): EN ISO 13485:2016
Medical devices - Quality management systems -
Requirements for regulatory purposes
(ISO 13485:2016)
DIN EN ISO 13485:2016

Facility(ies): Zhejiang Orient Gene Biotech Co., Ltd.
3787#, East Yangguang Avenue, Dipu Street Anji, 313300
Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate

HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma)

INTENDED USE

The HBsAg Rapid Test Cassette is a lateral flow chromatographic immunoassay for the qualitative detection of Hepatitis B surface antigen (HBsAg) in human whole blood, serum or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of infection with Hepatitis B virus (HBV). Any reactive specimen with the HBsAg Rapid Test Cassette must be confirmed with alternative testing method(s) and clinical findings.

INTRODUCTION

Viral hepatitis is a systemic disease primarily involving the liver. Most cases of acute viral hepatitis are caused by Hepatitis A virus, Hepatitis B virus (HBV) or Hepatitis C virus. The complex antigen found on the surface of HBV is called HBsAg. The presence of HBsAg in serum or plasma is an indication of an active Hepatitis B infection, either acute or chronic. In a typical Hepatitis B infection, HBsAg will be detected 2 to 4 weeks before the ALT level becomes abnormal and 3 to 5 weeks before symptoms or jaundice develop. HBsAg has four principal subtypes: adw, ayw, adr and ayr. Because of antigenic heterogeneity of the determinant, there are 10 major serotypes of Hepatitis B virus. The HBsAg Test Cassette (Whole Blood/Serum/Plasma) is a rapid test to qualitatively detect the presence of HBsAg in whole blood, serum or plasma specimens. The test utilizes a combination of double monoclonal antibodies to selectively detect elevated levels of HBsAg in whole blood, serum or plasma.

PRINCIPLE

The HBsAg Rapid Test Cassette is a lateral flow chromatographic immunoassay based on the principle of the double antibody-sandwich technique. The membrane is pre-coated with anti-HBsAg antibodies on the test line region of the test. During testing, Hepatitis B Surface Antigen in the whole blood, serum or plasma specimen reacts with the particle coated with anti-HBsAg antibody. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-HBsAg antibodies on the membrane and generate a colored line. The presence of this colored line in the test region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that the proper volume of specimen has been added and membrane wicking has occurred.

PRODUCT CONTENTS

The HBsAg Test Cassette (Whole Blood/Serum/Plasma) containing anti-HBsAg antibodies particles and anti-HBsAg antibodies coated on the membrane.

MATERIALS SUPPLIED

1. Test Cassette
2. Desiccant
3. Pipette Dropper
4. Buffer
5. Package Insert

MATERIAL REQUIRED BUT NOT PROVIDED

1. Specimen collection containers
2. Lancets (for fingerstick whole blood only)
3. Centrifuge (for plasma only)
4. Timer
5. Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

WARNINGS AND PRECAUTIONS

1. For professional In Vitro diagnostic use only. Do not use after expiration date.
2. Warning: the reagents in this kit contain sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to prevent azide build-up.
3. Do not use it if the tube/pouch is damaged or broken.

4. Test is for single use only. Do not re-use under any circumstances.
5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Humidity and temperature can adversely affect results.
8. Do not perform the test in a room with strong air flow, ie. electric fan or strong air conditioning.

SPECIMEN COLLECTION


1. HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.
2. To collect Fingerstick Whole Blood specimens:
 - Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.
 - Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
 - Puncture the skin with a new sterile lancet for each person. Wipe away the first sign of blood.
 - Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
 - Add the Fingerstick Whole Blood specimen to the test device by using a capillary tube:
 - Touch the end of the capillary tube to the blood until filled to approximately 50 µL. Avoid air bubbles.
 - Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the whole blood into the specimen well (S) of the test device.
 - Add the Fingerstick Whole Blood specimen to the test device by using hanging drops:
 - Position the patient's finger so that the drop of blood is just above the specimen well (S) of the test device.
 - Allow 2 hanging drops of fingerstick whole blood to fall into the center of specimen well (S) on the test device, or move the patient's finger so that the hanging drop touches the center of the specimen well (S). Avoid touching the finger directly to the specimen well (S).
3. Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.
4. Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
5. Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
6. If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

TEST PROCEDURE

Allow test device, specimen, buffer and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

1. Remove the test device from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
2. Place the test device on a clean and level surface.
 - For Serum or Plasma Specimens:** Hold the dropper vertically and transfer 2-3 drops of serum or plasma (approximately 60-90 µL) to the specimen well (S) of the test device. See illustration below.
 - For Venipuncture Whole Blood Specimens:** Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 50µL) to the specimen well (S) of the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.
 - For Fingerstick Whole Blood Specimens:** Allow 2 hanging drops of fingerstick whole blood (approximately 50 µL) to fall into the center of the specimen well (S) on the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.
3. Wait for the red line(s) to appear. The result should be read in 15 minutes. Do not interpret the result after 15 minutes.

HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma)



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

POSITIVE: Two distinct red lines appear. One line should be in the control region (C) and another line should be in the test region (T).

NEGATIVE: One red line appears in the control region (C). No apparent red or pink line appears in the test region (T).

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique.

Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. Though the HBsAg Rapid Test Cassette is a reliable screening assay, it should not be used as a sole criterion for diagnosis of HBV infection.
2. The HBsAg Rapid Test Cassette is limited to the qualitative detection of HBsAg in human whole blood, serum or plasma. The intensity of the test band does not have linear correlation with HBsAg titer in the specimen.
3. A negative test result does not preclude the possibility of exposure to or infection with HBV. Infection through recent exposure (seroconversion) to HBV may not be detectable.
4. A negative result can occur if the quantity of HBsAg present in the specimen is below the detection limits of the assay (lower than 1 ng/mL), or the HBsAg that are detected are not present during the stage of disease in which a sample is collected.
5. Interference due to heterophile antibodies, Rheumatoid Factors and other nonanalyte substances in patient's serum, capable of binding antibodies multivalently and providing erroneous analyte detection in immunoassays, has been reported in various studies. Both laboratory professionals and clinicians must be vigilant to this possibility of antibody interference. Results that appear to be internally inconsistent or incompatible with the clinical presentation should invoke suspicion of the presence of an endogenous artifact and lead to appropriate in vitro investigative action.
6. This kit is intended ONLY for testing of individual samples. Do not use it for testing of cadaver samples, saliva, urine or other body fluids, or pooled (mixed) blood.

7. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the result of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

PERFORMANCE CHARACTERISTICS

Sensitivity:

The HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma) has been tested with a sensitivity panel ranging from 0 to 300 ng/mL. All 10 HBsAg subtypes produced positive results on the HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma). The test can detect 5ng/mL of HBsAg in 10 minutes, and 1 ng/mL of HBsAg in 15 minutes.

Specificity:

Antibodies used for the HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma) were developed against whole Hepatitis B antigen isolated from Hepatitis B virus. Specificity of the HBsAg Rapid Test Cassette (Whole Blood/Serum/Plasma) was also tested with laboratory strains of Hepatitis A and Hepatitis C. They all yielded negative results.

HBsAg Rapid Test Cassette vs. EIA test

Method		EIA		Total Results
		Positive	Negative	
HBsAg Rapid Test Cassette	Positive	345	5	350
	Negative	2	980	982
Total Results		347	985	1332

Relative sensitivity: 99.4%

Relative specificity: 99.5%

Accuracy: 99.5%

REFERENCE

1. Blumberg, B. S. The Discovery of Australian Antigen and its relation to viral hepatitis. *Vitro*. 1971; 7: 223

HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma)

INTENDED USE

The HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) is a sandwich lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG, IgM, and IgA) anti- Hepatitis C virus (HCV) in human whole blood, serum or plasma. It is intended to be used as a screening test and as an aid in the diagnosis of infection with HCV. Any reactive specimen with the HCV Ab Rapid Cassette must be confirmed with alternative testing method(s) and clinical findings.

INTRODUCTION

Hepatitis C Virus (HCV) is a small, enveloped, positive-sense, single-stranded RNA Virus. Antibody to HCV is found in over 80% of patients with well-documented non-A, non-B hepatitis. Conventional methods fail to isolate the virus in cell culture or visualize it by electron microscope. Cloning the viral genome has made it possible to develop serologic assays that use recombinant antigens^(1, 2). Compared to the first generation HCV EIAs using single recombinant antigen, multiple antigens using recombinant protein and/or synthetic peptides have been added in new serologic tests to avoid nonspecific cross-reactivity and to increase the sensitivity of the HCV antibody tests^(3, 4).

HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) is a rapid test to qualitatively detect the presence of antibody to HCV in a whole blood, serum or plasma specimen. The test utilizes a combination of recombinant antigen to selectively detect elevated levels of HCV antibodies in whole blood, serum or plasma.

PRINCIPLE

The HCV Ab Rapid Test Cassette is a lateral flow chromatographic immunoassay based on the principle of the double antigen-sandwich technique. The test cassette consists of: 1) a burgundy colored conjugate pad containing HCV antigens conjugated with colloidal gold (HCV Ag conjugates) and rabbit IgG-gold conjugates, 2) a nitrocellulose membrane strip containing a test band (T band) and a control band (C band). The T band is pre-coated with non-conjugated HCV antigens, and the C band is pre-coated with goat anti-rabbit IgG. When an adequate volume of test specimen is dispensed into the sample well of the cassette, the specimen migrates by capillary action across the cassette. The antibodies: either the IgG, the IgM, or the IgA, to HCV if present in the specimen will bind to the HCV Ag conjugates. The immunocomplex is then captured on the membrane by the pre-coated HCV antigens, forming a burgundy colored T band, indicating a HCV Ab positive test result. Absence of the T band suggests a negative result. The test contains an internal control (C band) which should exhibit a burgundy colored band of the immunocomplex of goat anti-rabbit IgG/rabbit IgG-gold conjugate regardless the presence of any antibodies to HCV. Otherwise, the test result is invalid and the specimen must be retested with another device.

PRODUCT CONTENTS

HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) containing HCV antigen coated particles and HCV antigen coated on the membrane.

MATERIALS SUPPLIED

1. Test Strip 2. Pipette Dropper 3. Desiccant 4. Buffer 5. Package Insert

MATERIAL REQUIRED BUT NOT PROVIDED

1. Specimen collection containers 2. Lancets (for fingerstick whole blood only)
3. Centrifuge (for plasma only) 4. Timer
5. Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30°C). The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

WARNINGS AND PRECAUTIONS

1. For professional In Vitro diagnostic use only. Do not use after expiration date.
2. Warning: the reagents in this kit contain sodium azide which may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to

prevent azide build-up.

3. Do not use it if the tube/pouch is damaged or broken.

4. Test is for single use only. Do not re-use under any circumstances.

5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.

6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.

7. Humidity and temperature can adversely affect results .

SPECIMEN COLLECTION

1. The HCV Rapid Test Cassette (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.

2. To collect Fingerstick Whole Blood specimens:

• Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.

• Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.

• Puncture the skin with a new sterile lancet for each person. Wipe away the first sign of blood.

• Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.

• Add the Fingerstick Whole Blood specimen to the test device by using a capillary tube:

• Touch the end of the capillary tube to the blood until filled to approximately 50 µL. Avoid air bubbles.

• Place the bulb onto the top end of the capillary tube, then squeeze the bulb to dispense the whole blood into the specimen well (S) of the test device.

• Add the Fingerstick Whole Blood specimen to the test device by using hanging drops:

• Position the patient's finger so that the drop of blood is just above the specimen well (S) of the test device.

• Allow 2 hanging drops of fingerstick whole blood to fall into the center of specimen well (S) on the test device or, move the patient's finger so that the hanging drop touches the center of the specimen well (S). Avoid touching the finger directly to the specimen well (S).

3. Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.

4. Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.

5. Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.

6. If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

TEST PROCEDURE

Allow test device, specimen, buffer and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

1. Remove the test device from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.

2. Place the test device on a clean and level surface.


For Serum or Plasma Specimens: Hold the dropper vertically and transfer 1 drop of serum or plasma (approximately 30 µL) to the specimen well (S) of the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

For Venipuncture Whole Blood Specimens: Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 50 µL) to the specimen well (S) of the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

For Fingerstick Whole Blood Specimens: Allow 2 hanging drops of fingerstick whole blood (approximately 50 µL) to fall into the center of the specimen well (S) on the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.

HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma)

3. Wait for the red line(s) to appear. The result should be read in 15 minutes. Do not interpret the result after 15 minutes.



INTERPRETATION OF RESULTS

(please refer to the illustration above)

Positive: Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

Negative: One colored line appears in the control line region (C). No line appears in the test line region (T).

Invalid: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this test. However, it is recommended that positive and negative controls are sourced from a local competent authority and tested as a good laboratory practice, to confirm the test procedure and verify the test performance.

LIMITATIONS

1. The HCV Ab Rapid Test Cassette (Whole Blood/ Serum/Plasma) is for in vitro diagnostic use only. This test should be used for the detection of antibodies to HCV in whole blood, serum or plasma specimen.
2. The HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) will only indicate the presence of antibodies to HCV in the specimen and should not be used as the sole criteria for the diagnosis of Hepatitis C viral infection.
3. As with all diagnostic tests, all results must be considered with other clinical information available to the physician.
4. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended. A negative result at any time does not preclude the possibility of Hepatitis C Virus infection.
5. A negative result can occur if the quantity of the antibodies to HCV present in the specimen is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected.
6. Some specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results.

PERFORMANCE CHARACTERISTICS

Sensitivity: HCV Ab Rapid Test Cassette (Whole Blood/ Serum/Plasma) has passed a seroconversion panel and compared with leading commercial HCV EIA test using clinical specimens.

Specificity: The recombinant antigens used for HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) are encoded by genes for both structural (nucleocapsid) and non-structural proteins. HCV Ab Rapid Test Cassette (Whole Blood/Serum/Plasma) is highly specific for antibodies to Hepatitis C Virus compared with a leading

commercial HCV EIA test.

The HCV Ab Rapid Test Cassette vs EIA test

Method	EIA		Total Results
	Positive	Negative	
HCV Ab RapidTest	Positive	105	124
	Negative	2	1762
Total Results	107	1779	1886

Relative sensitivity: 98.1%

Relative specificity: 98.9%

Accuracy: 98.9%

REFERENCE

1. Choo, Q.L., G.Kuo,A.J. Weiner, L.R. Overby,D.W. Bradley, andM. Houghton. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 189;244:359
2. Kuo, G., Q.L. Choo, H.J. Alter, and M. Houghton. An assay for circulating antibodies to a major etiolog Virus of human non-A, non-B hepatitis. Science 1989; 244:362.
3. Van der Poel, C.L., H.T.M. Cuyper, H.W. Reesink, and P.N. Lelie .Confirmation of hepatitis C Virus infection by new four- antigen recombinant immunoblot assay. Lancet 1991;337:317
4. Wilber, J.C.Development and use of laboratory tests for hepatitis C infection: a review.J. Clin. Immunoassy 1993;16:204.



SYNTESYS S.A.S. DI RINALDO R. & C.

VIA G. GALILEI, 10/3
35037 Z.I. SELVE DI TEOLO (PD)
TEL. +39 049 9903866 R.A. FAX +39 049 9903867
COD. FISCALE P.IVA N.REG.IMP. PADOVA 03573950288
E-MAIL INFO@SYNTESYS.IT · WEB WWW.SYNTESYS.IT

DICHIARAZIONE DI CONFORMITA'
Conformity declaration



Il sottoscritto, Rinaldo Ruggero legale rappresentante della ditta:
The undersigned, Rinaldo Ruggero legal representative of the company:

produttore/manufacturer

SYNTESYS S.a.s. di Rinaldo R. & C.

indirizzo/address

Via G. Galilei, 10/3 35037 Zona Industriale SELVE DI TEOLO (PADOVA) ITALY

ò rappresentante il mandatario autorizzato entro la Unione Europea
or representing the authorized mandatary within the European Community

Mandatario autorizzato/authorized mandatary

indirizzo/address

Dichiara sotto la propria responsabilità che il prodotto/*declares under his own responsibility that the product:*

Denominazione/Description

Padella per ammalati, urinali uomo e donna, speculum vaginali, tamponcini cotonati, tamponi sterili in provetta, tamponi sterili con terreno Amies e Stuart in provetta/ *Bed pan, Urinal's man and woman, Vaginal speculum, Cotton swab, Sterile swab in test tube, Sterile swab with medium Amies or Stuart in test tube*

Materiale/Material

Polipropilene, Polietilene, Legno/ *Polypropylene, Polyethylene, Wood*

È conforme alle disposizioni della direttiva 93/42/CE e s.m.i. concernente i dispositivi medici ed al Decreto Legislativo di recepimento con D.lgs. del 24/02/1997 n° 46/97 e soddisfa a tutti i requisiti specificati.

Il dispositivo è stato classificato appartenente alla classe I° secondo i criteri stabiliti in base a quanto previsto dall'Art. 9 ed allegato IX della direttiva sopra citata /*It meets the EC Directive 93/42 about Medical Device, specifications established by the Italian law n 46/97, dated 24th February 1997. The device was classified as belonging to the 1st class, according to the specifications of the established by the art.9, IX enclosure of the above mentioned directive.*

Dichiara inoltre che la documentazione tecnica di supporto alla presente dichiarazione di conformità è conservata presso gli uffici dell'azienda e sarà posta alla disposizione di chi la richiede/ *declares that all technical documents attached to this conformity statment are filed in our company and can be consulted by any authorized body on demand.*

Data 07.01.2016
Issued on January 7th 2016

SYNTESYS S.A.S.
Il legale rappresentante
Rinaldo Ruggero



SYNTESSYS



SYNTESSYS S.A.S. DI RINALDO R. & C.
VIA G. GALILEI, 10/3
35037 Z.I. SELVE DI TEOLO (PD)

TEL. +39 049 9903866 R.A. FAX +39 049 9903867

COD.FISCALE P.IVA N.REG.IMP. PADOVA 03573950288
E-MAIL INFO@SYNTESSYS.IT - WEB WWW.SYNTESSYS.IT

DICHIARAZIONE DI CONFORMITA'
Conformity declaration



Il sottoscritto, Rinaldo Ruggero legale rappresentante della ditta:
The undersigned, Rinaldo Ruggero legal representative of the company:

produttore/manufacturer

SYNTESSYS S.a.s. di Rinaldo Ruggero & C.
indirizzo/address

Via G. Galilei, 10/3 35037 Zona Industriale SELVE DI TEOLO (PADOVA) ITALY

o rappresentante il mandatario autorizzato entro la Unione Europea or representing the authorized mandatary within the European Community

Mandatario autorizzato/authorized mandatary

indirizzo/address

Dichiara sotto la propria responsabilità che il prodotto/*declares under his own responsibility that the product:*

Denominazione degli
articoli
prodotti/*Description of
Manufacturer*

Contenitori per urina, contenitori per feci,
contenitori universali, Pipette Pasteur, Piastre di
Petri, Anse Sterili per batteriologia, Aste a "L",
Puntali Eppendorf gialli e blue, cuvette per
spettrofotometro, tazzine per campionamento siero,
bacchette per distacco ed estrazione del coagulo,
pinzette in polistirolo monouso, provette monouso in
plastica, tappi alettati per provette diam. 12 mm e
16mm, provette con granuli ed acceleratore, provette
sottovuoto per prelievo, Sistema SEDIPLAST,
Microprovette, Portavetrini, Vetrini precolorati,
Portaprovette, supporti per microprovette, bottiglie
per raccolta urine.

*Urine container, faeces container, universal
container, Pasteur pipette, Petri dishes, Sterile
loops, Sterile loops open "L", Eppendorf tips yellow
and blue, cuvettes for spectrophotometer, samples
cups, Rod to detach clot, disposable forceps,
Disposable plastic tubes, winged stoppers for tubes
diam. 12mm & 16mm, Test tube with granules and clot
activator, vacuum test tube, SEDIPLAST system,
micro test tubes, Slides Mailer, "TESTSIMPLETS" slide,
rack for test tubes, rack for micro test tubes,
Bottles for urine collection.*



SYNTESYS



ISO9001:2008
Cert. N. 6574/0

SYNTESYS S.A.S. DI RINALDO R. & C.
VIA G. GALILEI, 10/3
35037 Z.I. SELVE DI TEOLO (PD)
TEL. +39 049 9903866 R.A. FAX +39 049 9903867
COD.FISCALE P.IVA N.REG.IMP. PADOVA 03573950288
E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT

Materiale/ Material

**Polipropilene, Polistirolo, Polietilene e
Polimetilmetacrilato**

***Polypropylene, Polystyrene, Polyethylene and
Polymethylmetacrylate***

È conforme alle disposizioni della direttiva 98/79/CE concernente i dispositivi medici diagnostici in vitro e recepito in Italia con D.L. del 08/09/2000 n° 332 allegato 1 (requisiti essenziali) ed è fabbricato in accordo ai requisiti di cui all'Allegato III della sopra citata direttiva / *It meets the CE Directive 98/79 CE about in vitro diagnostic device specifications established by the Italian law n. 332, dated 8th September 2000. The device is made according to the specifications of the III attached of the above-mentioned directive.*

Dichiara inoltre che la documentazione tecnica di supporto alla presente dichiarazione di conformità è conservata presso gli uffici dell'azienda e sarà posta alla disposizione di chi la richiede/declares that all technical documents attached to this conformity statement are filed in our company and can be consulted by any authorized body on demand.

Data 07/01/2016
Issued on January 7th 2016

SYNTESYS S.a.s.
Il legale rappresentante
Rinaldo Ruggero



DICHIARAZIONE DI CONFORMITA' UE EU DECLARATION OF CONFORMITY

conforme all'Allegato IV del Regolamento (UE) 2017/746 "Dispositivi medico-diagnostici in vitro"
according to Annex IV of the Regulation (EU) 2017/746 "In vitro diagnostic medical devices"

fabbricante <i>manufacturer</i>	MEUS S.R.L.		
	articoli per laboratori analisi - disposable labware		
N° registrazione unico SRN	IT-MF-000021269		
indirizzo <i>address</i>	Via Leonardo da Vinci, 24/B-26, 35028 PIOVE DI SACCO (PD) - ITALIA		
telefono <i>phone</i>	+39-0499719511	fax <i>fax</i>	+39-0499719543
		posta elettronica <i>e-mail</i>	meus@tecnomeus.it

Identificazione dei prodotti **LITIO EPARINA X 10 ML SU PROVETTE PP 16X100 MM**

Product identification **LITHIUM HEPARIN FOR 10 ML OF BLOOD IN TEST TUBES 16X100 MM**

Destinazione d'uso **RACCOLTA DI CAMPIONI DI SANGUE PER I SUCCESSIVI TEST CHIMICO-CLINICI**

Intended use **COLLECTION OF BLOOD SAMPLES FOR SUBSEQUENT CHEMICAL-CLINICAL TESTS**

BASIC UDI-DI **805384899MTUBESWN**

CND **W050101010201**

numero di catalogo <i>part number</i>	18650	numero di lotto <i>batch number</i>	206578	scadenza <i>expiry date</i>	30/06/2024
--	--------------	--	---------------	--------------------------------	-------------------

classificazione dei prodotti **dispositivi non sterili rientranti nella classe A del regolamento 2017/746, conforme alla regola 5**

product identification **non sterile devices included in the class A regulation (EU) 2017/746, according to rule 5**

Si dichiara

sotto la propria esclusiva responsabilità che tutti i dispositivi sopraelencati rispettano le disposizioni applicabili dal regolamento 2017/746 Dispositivi Medico-Diagnostici In Vitro.

La documentazione tecnica richiesta dal succitato regolamento e quella comprovante il rispetto dei Requisiti generali di sicurezza e prestazione di cui all'Allegato I del Regolamento, sono conservati a cura del Fabbricante

Hereby we declare


Under our sole responsibility that the above mentioned devices meet the applicable provisions of the Regulation (EU) 2017/746 on "In vitro diagnostic medical devices"

The technical documentation, as required by Regulation (EU) 2017/746 and documents in order to prove conformity to general safety and performance requirements as listed in Annex I, are retained under the premises of the Manufacturer

luogo e data
place and date **PIOVE DI SACCO, 23/08/2022**

firma
signature **MEUS S.R.L.**
Quality Assurance
Giovanni Chiarin

Giovanni Chiarin



SYNTESSYS



Cert. N.7111/2



Cert. N.6574/2



SYNTESSYS S.R.L. UNIPERSONALE

VIA G. GALILEI, 10/3 - 35037 Z.I. SELVE DI TEOLO (PD)
TEL. +39 049 9903866 R.A. FAX +39 049 9903867
C.F./P.I./N.REG.IMP. PADOVA 03573950288
REA PD-320123 - CAP.SOC. 20.700,00€
E-MAIL INFO@SYNTESSYS.IT - WEB WWW.SYNTESSYS.IT
PEC POSTA@PEC.SYNTESSYS.IT

AUTHORIZATION LETTER

We, **Syntesys S.R.L.** having a registered office at Via G. Galilei 10/3, 35037 Selve di Teolo - PD - Italy, assign **Sanmedico SRL** having a registered office at A.Corobceanu str., apt. 9, Chişinău MD-2012, Moldova, as authorized representative.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This letter is valid till 31.12.2021

Teolo, 05.01.2021


 **SYNTESSYS S.R.L.**
UNIPERSONALE

Via G. Galilei, 10/3 - 35037 Z.I. Selve di Teolo (PD)
C.F./P.I./R.I. PD: 03573950288 - Cap. Soc. 20.700,00 €
Tel. 049.9903866 - Fax 049 9903867

Rinaldo Ruggero
CEO and Legal Representative
SYNTESSYS S.R.L.

Certificate

CISQ/ICIM S.P.A. has issued an IQNet recognized certificate that the organization:

SYNTESYS S.R.L.

Head Office and Operative Unit

Via G. Galilei, 10/1-2-3 - Zona Industriale - I-35037 Selve di Teolo (PD)

Operative Units

Via G. Galilei, 16/1 - Zona Industriale - I-35037 Selve di Teolo (PD)

Via San Benedetto, 48/A - Zona Industriale - I-35037 Selve di Teolo (PD)

Via G. Galilei, 3 - Zona Industriale - I-35037 Selve di Teolo (PD)

has implemented and maintains a/an

Quality Management System

for the following scope:

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

which fulfils the requirements of the following standard:

ISO 9001:2015

Issued on: **2022-06-05**

First issued on: **2013-06-05**

Expires on: **2025-06-04**

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document.

Registration Number: **IT-83562**



Alex Stoichitoiu
President of IQNET



Mario Romersi
President of CISQ



This attestation is directly linked to the IQNET Member's original certificate and shall not be used as a stand-alone document.

IQNET Members*:

AENOR Spain **AFNOR Certification** France **APCER** Portugal **CCC** Cyprus **CISQ** Italy **CQC** China **CQM** China **CQS** Czech Republic
Cro Cert Croatia **DQS Holding GmbH** Germany **EAGLE Certification Group** USA **FCAV** Brazil **FONDONORMA** Venezuela **ICONTEC**
Colombia **ICS** Bosnia and Herzegovina **Inspecta Sertifointi Oy** Finland **INTECO** Costa Rica **IRAM** Argentina **JQA** Japan **KFQ** Korea
LSQA Uruguay **MIRTEC** Greece **MSZT** Hungary **Nemko AS** Norway **NSAI** Ireland **NYCE-SIGE** México **PCBC** Poland **Quality Austria**
Austria **SII** Israel **SIQ** Slovenia **SIRIM QAS International** Malaysia **SQS** Switzerland **SRAC** Romania **TSE** Turkey **YUQS** Serbia

* The list of IQNET Members is valid at the time of issue of this certificate. Updated information is available under www.iqnet-certification.com

Certificate

CISQ/ICIM S.P.A. has issued an IQNet recognized certificate that the organization:

SYNTESYS S.R.L.

Head Office and Operative Unit

Via G. Galilei, 10/1-2-3 - Zona Industriale - I-35037 Selve di Teolo (PD)

Operative Units

Via G. Galilei, 16/1 - Zona Industriale - I-35037 Selve di Teolo (PD)

Via San Benedetto, 48/A - Zona Industriale - I-35037 Selve di Teolo (PD)

Via G. Galilei, 3 - Zona Industriale - I-35037 Selve di Teolo (PD)

has implemented and maintains a/an

Quality Management System

for the following scope:

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

which fulfils the requirements of the following standard:

ISO 13485:2016

Issued on: **2022-06-05**

First issued on: **2014-06-21**

Expires on: **2025-06-04**

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document.

Registration Number: **IT-93779**



Alex Stoichitoiu
President of IQNET



Mario Romersi
President of CISQ



This attestation is directly linked to the IQNET Member's original certificate and shall not be used as a stand-alone document.

IQNET Members*:

AENOR Spain **AFNOR Certification** France **APCER** Portugal **CCC** Cyprus **CISQ** Italy **CQC** China **CQM** China **CQS** Czech Republic
Cro Cert Croatia **DQS Holding GmbH** Germany **EAGLE Certification Group** USA **FCAV** Brazil **FONDONORMA** Venezuela **ICONTEC**
Colombia **ICS** Bosnia and Herzegovina **Inspecta Sertifointi Oy** Finland **INTECO** Costa Rica **IRAM** Argentina **JQA** Japan **KFQ** Korea
LSQA Uruguay **MIRTEC** Greece **MSZT** Hungary **Nemko AS** Norway **NSAI** Ireland **NYCE-SIGE** México **PCBC** Poland **Quality Austria**
Austria **SII** Israel **SIQ** Slovenia **SIRIM QAS International** Malaysia **SQS** Switzerland **SRAC** Romania **TSE** Turkey **YUQS** Serbia

* The list of IQNET Members is valid at the time of issue of this certificate. Updated information is available under www.iqnet-certification.com